Emergent BioSolutions | EBS - Betriebsaufwand





Betriebsaufwand Veränderung Datum
Acadia Pharmaceuticals USD 266.6M 23.72M 2025-12
Akebia Therapeutics USD 63.08M 8.26M 2025-12
ALKERMES USD 326.44M 1.41B 2025-12
Alnylam Pharmaceuticals USD 965.32M 84.27M 2025-12
Amarin USD 51.48M 113K 2025-12
ANI Pharmaceuticals USD 217.93M 287.88M 2025-12
BioMarin Pharmaceutical USD 676.18M 131.65M 2025-12
Coherus Biosciences USD 51.83M 2.48M 2025-12
Emergent BioSolutions USD 555.9M 242.7M 2023-06
Exelixis USD 362.75M 21.35M 2025-12
Glaxosmithkline GBP 9.17B 1.4B 2025-12
Heron Therapeutics USD 40.55M 1.46M 2025-12
Ionis Pharmaceuticals USD 418M 101.1M 2025-12
Ironwood Pharmaceuticals USD 57.33M 8.63M 2024-12
Lexicon Pharmaceuticals USD 20.27M 6.1M 2025-12
Lonza CHF 2.9B 184M 2025-06
Merck USD 10.16B 558M 2025-12
Moderna USD 1.54B 259M 2025-12
Myriad Genetics USD 212.8M 16.2M 2025-12
Nektar Therapeutics USD 40.9M 44.19M 2025-12
Neurocrine Biosciences USD 577.6M 22M 2025-12
Pacira USD 193.68M 27.32M 2025-12
Pfizer USD 12.91B 79.89B 2025-12
PTC Therapeutics USD 246.3M 38.78M 2025-12
Sanofi EUR 9.31B 1.2B 2026-03
Sarepta Therapeutics USD 853.02M 390.78M 2025-12
United Therapeutics USD 804.8M 5.79B 2025-12
Vanda Pharmaceuticals USD 466M 20.33M 2025-09
Xoma USD 22.84M 1.67M 2024-09